Abstract
The antidiabetic activity of AYU-DIA an Ayurvedic formulation was evaluated its hypoglycemic activity, glucose tolerance test (GTT) in normal rats, adrenaline induced hyperglycemic rats and alloxan induced diabetes insipidus albino Wistar rats1% CMC 1ml/kg po used as vehicle. In alloxan model rats were divided into five groups of 6 each. Diabetes was induced for all the groups (II, III, IV, V) except normal control (group I) by single intraperitoneal administration of alloxan monohydrate in rats (120 mg/kg.ip). AYU-Dia was administered orally at a dose of 105, 210mg/kg. to the group III and IV. The standard glibenclamide (4mg/kg po) was administered to the group V. The treatment was made for 7 days. Blood was withdrawn by tail vein puncture and blood glucose was estimated before and after 24 h the study period. The blood sugar was measured using glucometer and strips. . The AYU-DIA (105mg/kg.po) not showed hypoglycaemic effect when compared to normal rats. AYU-DIA (210mg/kg) showed significant decrease in the blood sugar level when compared to adrenaline induced hyperglycaemic rats. In glucose tolerance test (GTT) AYU-DIA treated rats showed decreased blood sugar levels. AYU-DIA (210mg/kg) treated rats showed significant decrease in the blood sugar level when compared to alloxan induced diabetic rats. The antidiabetic effect of AYU-DIA is may be due to protection of inhibition of glucokinase caused by the alloxan in the pancreatic beta cells. It may also due to prevention of ROS formation in the pancreatic beta cells.
